NYSE:ENZ Enzo Biochem - ENZ Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enzo Biochem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.35 -0.05 (-3.57%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.34▼$1.4750-Day Range$1.16▼$1.9852-Week Range$1.11▼$3.51Volume59,350 shsAverage Volume56,218 shsMarket Capitalization$65.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Enzo Biochem MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 3 Articles This WeekInsider TradingAcquiring Shares$213,520 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.26 out of 5 starsMedical Sector989th out of 1,026 stocksMedical Laboratories Industry22nd out of 24 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Enzo Biochem. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.93% of the float of Enzo Biochem has been sold short.Short Interest Ratio / Days to CoverEnzo Biochem has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Enzo Biochem has recently increased by 0.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEnzo Biochem does not currently pay a dividend.Dividend GrowthEnzo Biochem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENZ. Previous Next 2.3 News and Social Media Coverage News SentimentEnzo Biochem has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enzo Biochem this week, compared to 1 article on an average week.Search Interest3 people have searched for ENZ on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enzo Biochem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $213,520.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.50% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.56% of the stock of Enzo Biochem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Enzo Biochem is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enzo Biochem is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnzo Biochem has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enzo Biochem (NYSE:ENZ) StockEnzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.Read More Receive ENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZ Stock News HeadlinesFebruary 9, 2023 | marketwatch.comOxidative Stress Assay Market Size, Status, Global outlook 2023 To 2029February 8, 2023 | marketwatch.comOxidative Stress Assays Market Research Report 2023 by Size, Share, Product Type, Application, Region and Global Forecast to 2028February 8, 2023 | Altimetry (Ad)Massive “Heist” Could Sweep U.S. Banks in 2023Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 statesFebruary 8, 2023 | marketwatch.comClinical Reference Laboratory Services Market Analysis Report 2023 Along with Statistics Figures, till 2028February 7, 2023 | marketwatch.comRhodamine 123 Market Share Likely to Grow At a CAGRFebruary 1, 2023 | americanbankingnews.comEnzo Biochem, Inc. (NYSE:ENZ) Major Shareholder Buys $16,520.00 in StockFebruary 1, 2023 | americanbankingnews.comEnzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.comJanuary 29, 2023 | marketwatch.comNon-Radioactive Nucleic Acid Labeling Product Market Size, Sales, CAGR And Competition Data from 2023 To 2028 with Top Countries DataFebruary 8, 2023 | Altimetry (Ad)Massive “Heist” Could Sweep U.S. Banks in 2023Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 statesJanuary 23, 2023 | nasdaq.comJames Wolf Ups Stake in Enzo, May Seek Board SeatJanuary 18, 2023 | reuters.comENZ.DF - | Stock Price & Latest News | ReutersJanuary 16, 2023 | benzinga.comBiomarkers Market is expected to grow from USD 66.6 billion in 2022 to USD 183.42 billion by 2030 : GreyViewsDecember 17, 2022 | marketwatch.comClinical Reference Laboratory Services Market 2023-2028 : Leading Growth Drivers, Emerging Audience, Segments, Industry Sales, Profits & AnalysisDecember 16, 2022 | finance.yahoo.comEnzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Call TranscriptDecember 13, 2022 | seekingalpha.comEnzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call TranscriptDecember 13, 2022 | finanznachrichten.deEnzo Biochem, Inc.: Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business UpdateDecember 13, 2022 | marketwatch.comOligomycin Market 2023 : Size (value & volume) by Company, Key Regions, Type, and Application 2028December 13, 2022 | marketwatch.comQuizartinib Market 2023 : Industry Analysis, Opportunities, Technology, Top Players and Growth Forecast 2028December 12, 2022 | finance.yahoo.comEnzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business UpdateDecember 7, 2022 | finance.yahoo.comEnzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12thNovember 18, 2022 | finance.yahoo.comAs Enzo Biochem, Inc. (NYSE:ENZ) drops to US$100m market cap, insiders might rethink their US$3.1m stock purchase earlier this yearNovember 8, 2022 | finance.yahoo.comEnzo Biochem, Inc. Announces Date of Annual Shareholders’ MeetingOctober 24, 2022 | nasdaq.comShareholders in Enzo Biochem (NYSE:ENZ) are in the red if they invested five years agoOctober 20, 2022 | finance.yahoo.comEnzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFOOctober 17, 2022 | finance.yahoo.comThe past five years for Enzo Biochem (NYSE:ENZ) investors has not been profitableOctober 15, 2022 | finanznachrichten.deEnzo Biochem, Inc.: Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateOctober 14, 2022 | finance.yahoo.comEnzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZ Company Calendar Last Earnings12/12/2022Today2/08/2023Next Earnings (Estimated)3/13/2023Fiscal Year End7/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:ENZ CUSIPN/A CIK316253 Webwww.enzo.com Phone(212) 583-0100Fax212-679-7999Employees451Year Founded1976Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,260,000.00 Net Margins-26.89% Pretax Margin-26.89% Return on Equity-38.65% Return on Assets-22.26% Debt Debt-to-Equity Ratio0.09 Current Ratio1.84 Quick Ratio1.19 Sales & Book Value Annual Sales$107.07 million Price / Sales0.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book1.21Miscellaneous Outstanding Shares48,720,000Free Float41,168,000Market Cap$65.77 million OptionableOptionable Beta0.87 Social Links Key ExecutivesHamid ErfanianChief Executive Officer & DirectorKara CannonChief Operating OfficerPatricia EckertChief Financial OfficerDieter SchapfelChief Medical DirectorMatthew KupferbergSecretary & General CounselKey CompetitorsAkuminNASDAQ:AKUExagenNASDAQ:XGNSera PrognosticsNASDAQ:SERACentogeneNASDAQ:CNTGPsychemedicsNASDAQ:PMDView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 28,100 shares on 2/2/2023Ownership: 0.000%James G WolfBought 11,800 shares on 1/27/2023Total: $16,520.00 ($1.40/share)Hamid ErfanianBought 100,000 shares on 11/23/2022Total: $197,000.00 ($1.97/share)BlackRock Inc.Sold 62,134 shares on 11/15/2022Ownership: 3.013%Citadel Advisors LLCBought 31,700 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ENZ Stock - Frequently Asked Questions How have ENZ shares performed in 2023? Enzo Biochem's stock was trading at $1.43 at the start of the year. Since then, ENZ stock has decreased by 5.6% and is now trading at $1.35. View the best growth stocks for 2023 here. Are investors shorting Enzo Biochem? Enzo Biochem saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 344,100 shares, an increase of 9.1% from the December 15th total of 315,300 shares. Based on an average trading volume of 66,600 shares, the short-interest ratio is currently 5.2 days. Currently, 1.0% of the shares of the company are short sold. View Enzo Biochem's Short Interest. When is Enzo Biochem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our ENZ earnings forecast. How were Enzo Biochem's earnings last quarter? Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings results on Monday, December, 12th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter. The medical research company had revenue of $18.28 million for the quarter. Enzo Biochem had a negative net margin of 26.89% and a negative trailing twelve-month return on equity of 38.65%. What other stocks do shareholders of Enzo Biochem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU). What is Enzo Biochem's stock symbol? Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ." Who are Enzo Biochem's major shareholders? Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf, Kara Cannon and Peter J Iv Clemens. View institutional ownership trends. How do I buy shares of Enzo Biochem? Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enzo Biochem's stock price today? One share of ENZ stock can currently be purchased for approximately $1.35. How much money does Enzo Biochem make? Enzo Biochem (NYSE:ENZ) has a market capitalization of $65.77 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. How many employees does Enzo Biochem have? The company employs 451 workers across the globe. How can I contact Enzo Biochem? Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999. This page (NYSE:ENZ) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.